Biocept, Inc. (BIOC): Price and Financial Metrics


Biocept, Inc. (BIOC): $0.94

0.00 (-0.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BIOC POWR Grades


  • Value is the dimension where BIOC ranks best; there it ranks ahead of 94.62% of US stocks.
  • The strongest trend for BIOC is in Growth, which has been heading down over the past 179 days.
  • BIOC ranks lowest in Stability; there it ranks in the 5th percentile.

BIOC Stock Summary

  • With a market capitalization of $37,558,209, Biocept Inc has a greater market value than only 6.9% of US stocks.
  • As for revenue growth, note that BIOC's revenue has grown 139.55% over the past 12 months; that beats the revenue growth of 94.38% of US companies in our set.
  • Biocept Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -30.89%, greater than the shareholder yield of only 12.95% of stocks in our set.
  • Stocks that are quantitatively similar to BIOC, based on their financial statements, market capitalization, and price volatility, are AXGN, CSII, TRUE, XERS, and VAPO.
  • Visit BIOC's SEC page to see the company's official filings. To visit the company's web site, go to biocept.com.

BIOC Valuation Summary

  • BIOC's EV/EBIT ratio is -24.3; this is 182.94% lower than that of the median Healthcare stock.
  • Over the past 92 months, BIOC's price/sales ratio has gone down 304.2.
  • BIOC's price/sales ratio has moved down 304.2 over the prior 92 months.

Below are key valuation metrics over time for BIOC.

Stock Date P/S P/B P/E EV/EBIT
BIOC 2021-08-31 1.0 1.8 -24.2 -24.3
BIOC 2021-08-30 0.9 1.8 -23.6 -23.7
BIOC 2021-08-27 0.9 1.8 -23.5 -23.5
BIOC 2021-08-26 0.9 1.7 -23.2 -23.2
BIOC 2021-08-25 0.9 1.8 -23.5 -23.5
BIOC 2021-08-24 0.9 1.7 -22.6 -22.5

BIOC Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -53.06%.
  • Its 5 year revenue growth rate is now at 773.49%.
  • The 4 year price growth rate now stands at -99.39%.
BIOC's revenue has moved up $65,102,820 over the prior 67 months.

The table below shows BIOC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 65.7841 1.023974 2.049181
2021-09-30 65.7841 1.023974 3.100931
2021-06-30 54.90074 -5.005328 -2.20445
2021-03-31 43.77104 -13.66441 -6.866274
2020-12-31 27.4614 -19.7871 -17.80968
2020-09-30 10.73391 -24.15599 -25.44706

BIOC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BIOC has a Quality Grade of D, ranking ahead of 15.64% of graded US stocks.
  • BIOC's asset turnover comes in at 1.212 -- ranking 14th of 81 Healthcare stocks.
  • SSY, LH, and MGLN are the stocks whose asset turnover ratios are most correlated with BIOC.

The table below shows BIOC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.212 0.411 -0.069
2021-03-31 1.070 0.374 -0.312
2020-12-31 0.768 0.223 -1.341
2020-09-30 0.379 -0.323 -4.029
2020-06-30 0.239 -0.968 -4.770
2020-03-31 0.290 -0.903 -5.429

BIOC Price Target

For more insight on analysts targets of BIOC, see our BIOC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1.5 (Moderate Buy)

BIOC Stock Price Chart Interactive Chart >

Price chart for BIOC

BIOC Price/Volume Stats

Current price $0.94 52-week high $4.44
Prev. close $0.94 52-week low $0.84
Day low $0.89 Volume 52,500
Day high $0.97 Avg. volume 131,829
50-day MA $1.38 Dividend yield N/A
200-day MA $2.74 Market Cap 15.91M


BIOC Latest News Stream


Event/Time News Detail
Loading, please wait...

BIOC Latest Social Stream


Loading social stream, please wait...

View Full BIOC Social Stream

Latest BIOC News From Around the Web

Below are the latest news stories about Biocept Inc that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer

SAN DIEGO, February 22, 2022--Biocept highlights CNSide assay's ability to aid clinical research efforts to improve treatment of metastatic cancers involving brain.

Yahoo | February 22, 2022

Biocept, Inc. (NASDAQ:BIOC) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Biocept (NASDAQ:BIOC) has had a rough three months with its share price down 28%. However, the company's fundamentals...

Yahoo | February 18, 2022

Biocept appoints Samuel Riccitelli as interim president, CEO

Biocept (BIOC) appointed Samuel Riccitelli as interim president and CEO, succeeding Michael Nall.Riccitelli, who will remain chair of the board, recently served as CEO of Pathnostics,…

Seeking Alpha | February 16, 2022

Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer

SAN DIEGO, February 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall, and Antonino Morales as Interim Chief Financial Officer, succeeding Timothy C. Kennedy. Biocept also named M. Faye Wilson as Lead Independent Director of the company’s Board of Directors. Mr. Riccitelli remains Chair of the Board.

Yahoo | February 16, 2022

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

SAN DIEGO, February 10, 2022--Biocept names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer.

Yahoo | February 10, 2022

Read More 'BIOC' Stories Here

BIOC Price Returns

1-mo -33.33%
3-mo -58.59%
6-mo -75.52%
1-year -77.67%
3-year -90.96%
5-year -99.77%
YTD -74.03%
2021 -18.47%
2020 55.24%
2019 -66.74%
2018 -95.85%
2017 -10.39%

Continue Researching BIOC

Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:

Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5361 seconds.